Subscription Price SEK 0.38 for Warrants TO 6 in Dicot Pharma Determined; corresponding to SEK 0.19 per share

If all warrants of series TO 6 are exercised for the subscription of new shares, Dicot Pharma will receive approximately SEK 45.7 million before issuance costs. To prevent the warrants from expiring worthless, the holder must actively subscribe for shares by March 31, 2025, or alternatively sell the warrants by March 27, 2025. Please note that some custodians may close their application process earlier than March 31, 2025.

The full terms and conditions regarding the warrants are available on Dicot Pharma's website www.dicotpharma.com.

Background
Over the past year, Dicot Pharma has achieved several key milestones in its development of the company and the erectile dysfunction drug candidate LIB-01. The phase 1 study showed prominent clinical results and a phase 2a study has been initiated and is ongoing. Dicot Pharma has also been granted a new patent family in the US that extends to 2042. In addition, new research findings have been made in the field of metabolic diseases, where conditions such as obesity and diabetes can be accommodated.

With these advancements as a foundation, Dicot Pharma now looks forward to the next stages of development. The upcoming key activities include finalizing and reporting the results of the phase 2a study, which is expected to be completed in mid-2025. Preparations for a phase 2b study are ongoing in parallel, with an expected start in 2026. To strengthen the company's long-term position in the market, work on internationalization and preparations for future commercialization is also being intensified. Evaluation and development of new indications to broaden the product portfolio is also in focus.

Through Dicot Pharma's rights issue, which concluded on August 30, 2024, and the subsequent compensation issue decided by the Board on September 9, 2024, a total of 120,152,251 warrants of series TO 6 were issued. The subscription price is set at SEK 0.19 per share, meaning that Dicot Pharma will receive approximately SEK 45.7 million before issuance costs if all warrants are exercised. The proceeds from this warrant program will be a significant contribution that will allow us to maintain the high speed forward and bring Dicot Pharma ever closer to launch. The proceeds will be allocated as follows:

• Co-financing of the clinical phase 2b study, scaling of the supply chain, and other preparations to make the company phase 3-ready as soon as possible (approximately 80%).
• Evaluation and development to expand the product portfolio with new indications, including metabolic diseases (approximately 20%).

Summary of Terms for Warrants of Series TO 6

• Subscription period: March 17-31, 2025. Please note that some custodians may close their application process earlier than March 31, 2025.
• Terms: One warrant of series TO 6 entitles to subscribe for two new shares.
• Subscription price: SEK 0.19 per share.
• Last trading day for TO 6 warrants: March 27, 2025. Until then, it is possible to both buy more and sell TO 6. The warrants are listed on Nasdaq First North under the name "DICOT TO 6".
• Issuance volume: 120,152,251 TO 6 warrants entitling subscription of 240,304,502 shares. If all warrants are exercised, Dicot Pharma will receive approximately SEK 45.7 million before issuance costs.
• Dilution: The dilution in the event of full exercise of the warrants corresponds to approximately 11.9% of the number of shares and votes in Dicot Pharma.

The full terms and conditions regarding the warrants are available on Dicot Pharma's website www.dicotpharma.com.

How to Exercise the Warrants
a) Holders of nominee-registered warrants (held in a custody account, e.g., Avanza, Nordnet, or bank):

Subscription and payment by exercising the warrants shall be carried out in accordance with the instructions from each respective custodian. Please contact your custodian for further information.

b) Holders of directly registered warrants (held in a VP account):

A pre-printed subscription form will be sent out. Subscription shall be made through simultaneous cash payment according to the instructions on the subscription form. The subscription form with payment instructions will be available on Dicot Pharma's website www.dicotpharma.com and on Aqurat Fondkommission's website www.aqurat.se.

Outcome
The outcome of the warrant exercise will be announced through a press release around April 2, 2025. Shares that have been subscribed for and paid will be registered in the subscriber's securities account as interim shares (IA) until the registration of the issuance has been completed with the Swedish Companies Registration Office, upon which the interim shares will automatically be converted into shares in Dicot Pharma AB.

Advisors
Corpura Fondkommission AB, www.corpura.se, is the financial advisor and Advokatfirman Lindahl KB is the legal advisor in connection with the warrant exercise. Aqurat Fondkommission AB acts as the issuing agent.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. 

Dicot Pharma is listed on Nasdaq First North and has approximately 8,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.